Domestic major pharmaceutical firms favors strategic partnership with promising venture

Published: 2002-05-27 06:58:00

Updated: 2002-05-27 06:58:00

The Korea Drug Research Association (KDRA) says that its15-day survey conducted on last month disclosed that 97 percent of its 28 members polled said they would agree with the necessity of outsourcing for their R&D new drug projects and better competitiveness and promising bioventure firms would ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK